

Khashayar Esfahani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8244611/publications.pdf>

Version: 2024-02-01

24
papers

839
citations

759233

12
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

1523
citing authors

#	ARTICLE	IF	CITATIONS
1	Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report. , 2021, 9, e001831.		4
2	Reply to “Personalized treatment of immune-related adverse events” balance is required™. Nature Reviews Clinical Oncology, 2020, 17, 518-518.	27.6	4
3	Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. New England Journal of Medicine, 2020, 382, 2374-2375.	27.0	54
4	Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology, 2020, 17, 504-515.	27.6	189
5	A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer.. Journal of Clinical Oncology, 2020, 38, 3581-3581.	1.6	8
6	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nature Communications, 2019, 10, 4712.	12.8	76
7	Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. New England Journal of Medicine, 2019, 380, 2375-2376.	27.0	162
8	Adverse events associated with immune checkpoint inhibitor treatment for cancer. Cmaj, 2019, 191, E40-E46.	2.0	36
9	Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.. Journal of Clinical Oncology, 2019, 37, 9561-9561.	1.6	2
10	A phase I open prospective cohort trial of curcumin plus tyrosine kinase inhibitors for EGFR-mutant advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e20611-e20611.	1.6	6
11	Programmed Cell Death Ligand 1 “Induced Coma From Diffuse Cerebritis. Journal of Oncology Practice, 2018, 14, 134-135.	2.5	4
12	Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression. Journal of Oncology Practice, 2018, 14, 514-516.	2.5	13
13	Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis. , 2018, 6, 154.		3
14	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers, 2018, 10, 204.	3.7	37
15	Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. New England Journal of Medicine, 2017, 376, 1989-1991.	27.0	154
16	Erdheim-Chester Disease: The Importance of Information Integration. Case Reports in Oncology, 2017, 10, 613-619.	0.7	7
17	Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. BMJ Case Reports, 2016, 2016, bcr2016215525.	0.5	5
18	HSP90 as a novel molecular target in non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2016, 7, 11.	2.7	19

#	ARTICLE	IF	CITATIONS
19	Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. PLoS ONE, 2016, 11, e0167906.	2.5	13
20	An unusual cause of STEMI and cardiac tamponade. BMJ Case Reports, 2014, 2014, bcr2014206926-bcr2014206926.	0.5	0
21	A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Frontiers in Oncology, 2014, 4, 174.	2.8	22
22	Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary. BMJ Case Reports, 2014, 2014, bcr2014204287-bcr2014204287.	0.5	6
23	Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+ breast cancer.. Journal of Clinical Oncology, 2014, 32, e11585-e11585.	1.6	0
24	Acute Liver Failure Because of Chronic Lymphocytic Leukemia: Case Report and Review of the Literature. Current Oncology, 2011, 18, 39-42.	2.2	15